Skip to main content
. 2016 Apr 27;11(4):e0153919. doi: 10.1371/journal.pone.0153919

Fig 3. JNK regulates the effect of rosuvastatin’s rescue of the CD40L stimulated P4Hα1 inhibition in CD40L-stimulated HASMCs.

Fig 3

(A, B and C) The phosphorylation levels of JNK (A), ERK (B), and p38 MAPK (C) in HASMCs treated with 5μg/ml rhsCD40L for 0, 5, 15, 30 and 120 min western blot analysis. (D and E) P4Hα1 expression in HASMCs treated with or without rhsCD40L, JNK siRNA and rousuvastatin by qRT-PCR (D) and western blot analysis (E). (F, G and H) JNK (F), ERK (G) and p38 MAPK (H) protein expression in HASMCs transfected with or without target siRNA and negative control siRNA. (I) The phosphorylation levels of JNK in HASMCs treated with or without rhsCD40L and rosuvastatin. *P < 0.05 vs. control, #P <0.05 vs. CD40L, &P<0.05 vs. CD40L+siRNA. N.C: the group transfected with negative control siRNA.